Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.

Eyres M. et al, (2021), Gastroenterology, 161, 653 - 668.e16

The Potential of Artificial Intelligence to Detect Lymphovascular Invasion in Testicular Cancer.

Ghosh A. et al, (2021), Cancers (Basel), 13

Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments.

Kanellakis NI. et al, (2020), Thorax, 75, 1004 - 1008

The Repertoire of Serous Ovarian Cancer Non-genetic Heterogeneity Revealed by Single-Cell Sequencing of Normal Fallopian Tube Epithelial Cells.

Hu Z. et al, (2020), Cancer Cell, 37, 226 - 242.e7

Enriched HLA-E and CD94/NKG2A interaction limits antitumor CD8+ tumor-infiltrating T lymphocyte responses.

Abd Hamid M. et al, (2019), Cancer Immunol Res

A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer.

Li X. et al, (2019), Front Oncol, 9

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.

Alton EWFW. et al, (2017), Thorax, 72, 137 - 147

A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis

Alton EWFW. et al, (2016), Efficacy and Mechanism Evaluation

Transgene sequences free of CG dinucleotides lead to high level, long-term expression in the lung independent of plasmid backbone design.

Bazzani RP. et al, (2016), Biomaterials, 93, 20 - 26

A Phase I/IIa Safety and Efficacy Study of Nebulized Liposome-mediated Gene Therapy for Cystic Fibrosis Supports a Multidose Trial.

Alton EWFW. et al, (2015), Am J Respir Crit Care Med, 192, 1389 - 1392

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF REPEATED NEBULISATION OF NON-VIRAL CFTR GENE THERAPY IN PATIENTS WITH CYSTIC FIBROSIS

Alton E. et al, (2015), PEDIATRIC PULMONOLOGY, 50, 262 - 262

PRODUCTION OF SIV.F/HN: A NEW LENTIVIRUS VECTOR FOR CF GENE THERAPY

Hyde SC. et al, (2015), PEDIATRIC PULMONOLOGY, 50, 291 - 291

Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.

Alton EWFW. et al, (2015), Lancet Respir Med, 3, 684 - 691

Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: A randomised, double-blind, placebo-controlled, phase 2b trial

Alton EWFW. et al, (2015), The Lancet Respiratory Medicine, 3, 684 - 691

DEVELOPMENT OF AN OPTIMAL F/HN PSEUDOTYPED SIV VECTOR FOR CF GENE THERAPY

Hyde SC. et al, (2014), THORAX, 69, A165 - A166

Assessment of immune responses to single and repeat dose aeroslisation of the non-viral formualtion PGM169/GL67A in cystic fibrosis patients

Griesenbach U. et al, (2014), HUMAN GENE THERAPY, 25, A110 - A111

Development of F/HN pseudotyped Lentivirus for airway gene transfer

Gill DR. et al, (2014), HUMAN GENE THERAPY, 25, A43 - A43

Results of a Phase IIb non-viral gene therapy trial from the UK CF Gene Therapy Consortium

Griesenbach U. et al, (2014), HUMAN GENE THERAPY, 25, A51 - A51

LARGE-SCALE PRODUCTION OF LENTIVIRAL VECTORS FOR CF LUNG GENE THERAPY

Davies LA. et al, (2014), PEDIATRIC PULMONOLOGY, 49, 293 - 293

MOLECULAR ANALYSES OF VECTOR DELIVERY AND GENE EXPRESSION IN A MULTIDOSE TRIAL OF NON-VIRAL GENE THERAPY IN PATIENTS WITH CF

Sumner-Jones SG. et al, (2014), PEDIATRIC PULMONOLOGY, 49, 302 - 302

Load More

Include forthcoming?